Dependency of Tamoxifen Sensitive and Resistant ER+ Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth

被引:3
|
作者
Bhasin, Satyam [1 ,2 ]
Dusek, Christopher [1 ,2 ]
Peacock, James W. [1 ,2 ]
Cherkasov, Artem [1 ,2 ]
Wang, Yuzhuo [1 ,2 ]
Gleave, Martin [1 ,2 ]
Ong, Christopher J. [1 ,2 ]
机构
[1] Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada
[2] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada
关键词
ER+ breast cancer; Semaphorin; 3C; plexin-B1; siRNA knockdown; Akt-MAPK signaling; apoptosis; B1SP; tamoxifen-resistance; EXPRESSION; MECHANISMS; IMPACT;
D O I
10.3390/cells12131715
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Estrogen receptor positive (ER+) breast cancer (BCa) accounts for the highest proportion of breast cancer-related deaths. While endocrine therapy is highly effective for this subpopulation, endocrine resistance remains a major challenge and the identification of novel targets is urgently needed. Previously, we have shown that Semaphorin 3C (SEMA3C) is an autocrine growth factor that drives the growth and treatment resistance of various cancers, but its role in breast cancer progression and endocrine resistance is poorly understood. Here, we report that SEMA3C plays a role in maintaining the growth of ER+ BCa cells and is a novel, tractable therapeutic target for the treatment of ER+ BCa patients. Analyses of publicly available clinical datasets indicate that ER+ BCa patients express significantly higher levels of SEMA3C mRNA than other subtypes. Furthermore, SEMA3C mRNA expression was positively correlated with ESR1 mRNA expression. ER+ BCa cell lines (MCF7 and T47D) expressed higher levels of SEMA3C mRNA and protein than a normal mammary epithelial MCF10A cell line. ER siRNA knockdown was suppressed, while dose-dependent beta-estradiol treatment induced SEMA3C expression in both MCF7 and T47D cells, suggesting that SEMA3C is an ER-regulated gene. The stimulation of ER+ BCa cells with recombinant SEMA3C activated MAPK and AKT signaling in a dose-dependent manner. Conversely, SEMA3C silencing inhibited Estrogen Receptor (ER) expression, MAPK and AKT signaling pathways while simultaneously inducing apoptosis, as monitored by flow cytometry and Western blot analyses. SEMA3C silencing significantly inhibited the growth of ER+ BCa cells, implicating a growth dependency of ER+ BCa cells on SEMA3C. Moreover, the analysis of tamoxifen resistant (TamR) cell models (TamC3 and TamR3) showed that SEMA3C levels remain high despite treatment with tamoxifen. Tamoxifen-resistant cells remained dependent on SEMA3C for growth and survival. Treatment with B1SP Fc fusion protein, a SEMA3C pathway inhibitor, attenuated SEMA3C-induced signaling and growth across a panel of tamoxifen sensitive and resistant ER+ breast cancer cells. Furthermore, SEMA3C silencing and B1SP treatment were associated with decreased EGFR signaling in TamR cells. Here, our study implicates SEMA3C in a functional role in ER+ breast cancer signaling and growth that suggests ER+ BCa patients may benefit from SEMA3C-targeted therapy.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] SEMAPHORIN 3C KNOCKDOWN USING AN ANTISENSE OLIGONUCLEOTIDE INDUCES APOPTOSIS AND CHEMOSENSITIZES IN BLADDER CANCER
    Takeuchi, Ario
    Shiota, Masaki
    Inokuchi, Junnichi
    Eto, Masatoshi
    JOURNAL OF UROLOGY, 2020, 203 : E6 - E7
  • [32] Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis
    Xie, Xuemei
    Lee, Jangsoon
    Fuson, Jon A.
    Liu, Huey
    Gi, Young J.
    Poullikkas, Thanasis
    Fan, Pang-Dian
    Koyama, Kumiko
    Tripathy, Debu
    Ueno, Naoto T.
    CANCER RESEARCH, 2023, 83 (08)
  • [33] PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells
    Ito, Koichi
    Park, Sun Hee
    Katsyv, Igor
    Zhang, Weijia
    De Angelis, Carmine
    Schiff, Rachel
    Irie, Hanna Y.
    NPJ BREAST CANCER, 2017, 3
  • [34] Semaphorin 3C knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes in bladder cancer
    Takeuchi, Ario
    Shiota, Masaki
    Ong, Christopher
    Cleave, Martin
    Inokuchi, Junichi
    Eto, Masatoshi
    CANCER SCIENCE, 2021, 112 : 842 - 842
  • [35] PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells
    Koichi Ito
    Sun Hee Park
    Igor Katsyv
    Weijia Zhang
    Carmine De Angelis
    Rachel Schiff
    Hanna Y. Irie
    npj Breast Cancer, 3
  • [36] Investigation of a tamoxifen-RACK7/KDM5C-IFN-I axis for ER+ breast cancer immunomodulation
    Aberin, Marvin Angelo Esteban
    Singh, Saurabh
    Lee, Yu-Ling
    Lin, Kun-Yuan
    Chang, Yao-Ming
    Guha, Chandan
    Wang, Shu-Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 9 - 9
  • [37] Polarity protein SCRIB interacts with SLC3A2 to regulate proliferation and tamoxifen resistance in ER+ breast cancer
    Yasuhiro Saito
    Shiori Matsuda
    Naomi Ohnishi
    Keiko Endo
    Sanae Ashitani
    Maki Ohishi
    Ayano Ueno
    Masaru Tomita
    Koji Ueda
    Tomoyoshi Soga
    Senthil K. Muthuswamy
    Communications Biology, 5
  • [38] Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer
    Tam, Kevin J.
    Liu, Liangliang
    Hsing, Michael
    Dalal, Kush
    Thaper, Daksh
    McConeghy, Brian
    Yenki, Parvin
    Bhasin, Satyam
    Peacock, James W.
    Wang, Yuzhuo
    Cherkasov, Artem
    Rennie, Paul S.
    Gleave, Martin E.
    Ong, Christopher J.
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [39] Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer
    Kevin J. Tam
    Liangliang Liu
    Michael Hsing
    Kush Dalal
    Daksh Thaper
    Brian McConeghy
    Parvin Yenki
    Satyam Bhasin
    James W. Peacock
    Yuzhuo Wang
    Artem Cherkasov
    Paul S. Rennie
    Martin E. Gleave
    Christopher J. Ong
    Scientific Reports, 14
  • [40] Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
    Seo Yun Moon
    Heejin Lee
    Seoree Kim
    Ji Hyung Hong
    Sang Hoon Chun
    Hee Yeon Lee
    Keunsoo Kang
    Ho Shik Kim
    Hye Sung Won
    Yoon Ho Ko
    BMC Cancer, 21